✦ LIBER ✦

Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials

✍ Scribed by Wen-Bin Zhou; Qiang Ding; Ling Chen; Xiao-An Liu; Shui Wang

Publisher: Springer US
Year: 2011
Tongue: English
Weight: 375 KB
Volume: 128
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-011-1556-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized adjuvant trial to evaluate th

Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer: 5-year results from the nishi-nippon group of the adjuvant chemoendocrine therapy for breast cancer organization

✍ Masakazu Toil; Takao Hattori; Masanobu Akagi; Kiyoshi Lnokuchi; Kunzo Orita; Kei 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 714 KB

Background. A randomized adjuvant trial was conducted from October 1982 to January 1985 to evaluate the addition of tamoxifen (TAM) to combination chemotherapy with perioperative mitomycin C (MMC) and ftorafur (FT) for patients with estrogen receptor (ER)-positive tumors and the addition of PSK, a b

Anastrozole is superior to tamoxifen as

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma : Results of two randomized trials designed for combined analysis

✍ Jacques Bonneterre; Aman Buzdar; Jean-Marc A. Nabholtz; John F. R. Robertson; Be 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB 👁 2 views